<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01216839</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001CBR08T</org_study_id>
    <nct_id>NCT01216839</nct_id>
  </id_info>
  <brief_title>Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue Sarcomas</brief_title>
  <official_title>Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue Sarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidnei Epelman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Santa Marcelina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the Everolimus aim response in children and
      adolescents with refractory or relapsed Rhabdomyosarcoma and other soft tissue sarcomas
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the Everolimus aim response in children and adolescents with refractory and relapsed Rhabdomyosarcoma and other soft tissue sarcomas</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Define Everolimus toxicity in this population</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Refractory or Relapsed RMS and Soft Tissue Sarcomas</condition>
  <arm_group>
    <arm_group_label>Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Everolimus will be administered every day, initial dose 5 mg/m²/day, in 28 days cycle. Maximum dose: 10 mg/day. The cycles will be repeated till progression disease or untolerable toxicity.</description>
    <arm_group_label>Everolimus</arm_group_label>
    <other_name>Afinitor, RAD</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Rhabdomyosarcoma and other soft tissue sarcoma histological confirmation.

          -  No option of known curative treatment, neither approved treatment that increases
             survival with adequate quality of life.

          -  Karnofsky scale ≥ 50 for patients over 16 years and Lansky scale ≥ 50 for patients
             under 16 years old.

          -  Subjects shouldn't have received antineoplasic therapy &lt; 4 weeks before study
             treatment initiation.

          -  Adequate hematological function: neutrophil count &gt; 1.500/mm³ and hemoglobin &gt; 8.0
             mg/dL.

          -  Adequate renal function, as defined below:

        Age Maximum serum creatinine (mg/dL) 0 - 29 days 0,4 - 0,7 1 month - 3 years 0,7 4 - 7
        years 0,8 8 - 10 years 0,9 11 - 12 years 1,0 13 - 17 years 1,2

        ≥ 18 years 1,3

          -  Adequate hepatic function: total bilirubin ≤ 1.5 x ULN.

          -  Patient and/or legal responsible must sign ICF.

          -  Life expectation &gt; 8 weeks.

          -  Measurable disease, according to RECIST criteria.

          -  For female patients of childbearing age: presence of a negative pregnancy test within
             7 days prior to day 0.

          -  The patient agrees to use effective contraception if procreative potential exists. Use
             of reliable means of contraception (e.g. hormonal contraceptive, patch, vaginal ring,
             intrauterine device, physical barrier, abstinence)for subjects of reproductive
             potential (male and female) is required during study treatment and for 3 months
             following last dose of study drug.

        Exclusion Criteria:

          -  History of myocardial infarction, angina and cerebrovascular accident related to
             atherosclerosis.

          -  Pulmonary disorder(e.g. FEV1 ou DLCO ≤ 70% from expected).

          -  Significant hematologic or hepatic abnormality (transaminases levels &gt; 2.5 x ULN or
             serum bilirubin &gt; 1.5 x ULN, hemoglobin &lt; 8 g/dL, platelets &lt; 100.000/mm³, ANC &lt;
             1.500/mm³.

          -  Has other existing serious medical conditions that could adversely affect the ability
             of the patient to be treated in accordance with the protocol.

          -  Any condition, therapy, or medical condition, which, in the opinion of the attending
             physician could represent a risk for the patient or adversely affect the study
             objectives.

          -  If female, is pregnant or lactating.

          -  Active infection at the moment of recruitment.

          -  Previous history of organ transplantation.

          -  Recent surgery &lt; 2 months before entering study.

          -  Concomitant antineoplasic therapy.

          -  Patient received more than one rescue treatment, previously.

          -  Previous treatment with mTor inhibitors (ex: sirolimus, temsirolimus, everolimus).

          -  Use of investigational drug &lt; 30 days before entering study.

          -  Non-controlled hyperlipidaemia: serum cholesterol (fasting) &gt; 300 mg/dL or 7,75 mmol/L
             and triglycerides (fasting) &gt; 2,5 x ULN.

          -  Non-controlled Diabetes Mellitus defined as: glycemia (fasting) &gt; 1,5 x ULN.

          -  Patient with hemorrhagic disorder or using oral anti-vitamin K (except Warfarin in low
             doses).

          -  Patient with HIV infection.

          -  Incapable to perform protocol visits.

          -  Another neoplasia for the last 2 years (except squamous or basocellular skin cancer).

          -  Hypersensitivity history to rapamycin analogs.

          -  Chronic treatment with corticoids (except per oral, topical or local treatment) or
             another immunosuppressor agent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sidnei Epelman, MD</last_name>
    <phone>+55 11 2522-2472</phone>
    <email>pesquisaoncoped@santamarcelina.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Casa de Saúde Santa Marcelina</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>08270070</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sidnei Epelman, MD</last_name>
      <phone>+55 11 2522-2472</phone>
      <email>pesquisaoncoped@santamarcelina.org</email>
    </contact>
    <investigator>
      <last_name>Sidnei Epelman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2010</study_first_submitted>
  <study_first_submitted_qc>October 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2010</study_first_posted>
  <last_update_submitted>March 25, 2013</last_update_submitted>
  <last_update_submitted_qc>March 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Santa Marcelina</investigator_affiliation>
    <investigator_full_name>Sidnei Epelman</investigator_full_name>
    <investigator_title>Director of Pediatric Oncology Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Rhabdomyosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

